Financial News

MedX Announces $500,000 Non-Brokered Private Placement of Convertible Debenture Loan Notes to Redeem Existing Secured Loan

Products You May Like

Article content material

MISSISSAUGA, Ontario — MedX Well being Corp. (“MedX” or the “Firm”) (TSX-V: MDX) publicizes that, topic to TSX-V Acceptance, it has entered into an settlement to redeem an present $500,000 secured mortgage by the use of a non-brokered Personal Placement of 10 Convertible Debenture Mortgage Notes, every with a face worth of $50,000 (“Convertible Notes”) to the identical accredited investor. The Convertible Notes, which have related phrases to the Mortgage Notes issued by the Firm in February, 2021, bear curiosity at 6% per 12 months, payable Quarterly, and can mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes could also be transformed, on the choice of the Holder, into models at $0.14 per unit (“Unit”) at any time till the Maturity Date. Every Unit will probably be comprised of One (1) totally paid Frequent Share and One-half (1/2) of a Share Buy Warrant. Every complete Share Buy Warrant will probably be exercisable to buy One (1) additional Frequent Share on the value of $0.20, exercisable for a interval expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are topic to restriction from buying and selling for a interval of 4 months and someday from the date of issuance. No brokers’ charges or commissions are payable on this transaction. Closing of the Placement will probably be topic to receipt of all related regulatory and Inventory Change approvals or acceptances.

Article content material

About MedX

MedX, headquartered in Mississauga, Ontario, is a number one medical system and software program firm targeted on pores and skin well being with its SIAscopy® on DermSecure® telemedicine platform, using its SIAscopy® expertise. SIAscopy® can be imbedded in SIAMETRICS®, a well-regarded analysis system used to evaluate remedy effectiveness of quite a lot of pores and skin situations, together with burns. The Firm’s SIAscope® and different units are manufactured in its ISO 13485 licensed facility. The SIAscope® is a hand-held system that makes use of patented expertise using mild and its remittance to view as much as 2 mm beneath suspicious moles and lesions in a ache free, non-invasive method, with the Firm’s software program then creating real-time pictures for physicians and dermatologists to judge all varieties of moles or lesions inside seconds. These merchandise are Well being Canada, FDA, TGA and CE cleared to be used in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. DermSecure® meets all privateness, safety and related regulatory necessities in Canada, the US, Brazil, and the EU. MedX additionally designs, manufactures and distributes high quality photobiomodulation therapeutic and dental lasers to supply drug-free and non-invasive remedy of tissue harm and ache.

Ahead-looking Statements

This press launch doesn’t represent a proposal of any securities on the market. This press launch incorporates sure forward-looking statements inside the which means of relevant Canadian securities laws. These forward-looking statements contain sure dangers and uncertainties that might trigger precise outcomes to vary, together with, with out limitation, the corporate’s restricted working historical past and historical past of losses, the shortcoming to efficiently acquire additional funding, the shortcoming to lift capital on phrases acceptable to the corporate, the shortcoming to compete successfully within the market, the shortcoming to finish the proposed acquisition and such different dangers that might trigger the precise outcomes to vary materially from these contained within the firm’s projections or forward-looking statements. All ahead wanting statements on this press launch are primarily based on data obtainable to the corporate as of the date hereof, and the corporate undertakes no obligation to replace forward-looking statements to mirror occasions or circumstances occurring after the date of this press launch.

Neither TSX Enterprise Change nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Change) accepts duty for the adequacy or accuracy of this press launch.

View supply model on



Rob von der Porten, Chairman and Appearing CEO
MedX Well being Corp

Invoice Mitoulas, Investor Relations
MedX Well being Corp

Products You May Like